Compare ANEB & BTMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANEB | BTMD |
|---|---|---|
| Founded | 2020 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 96.8M | 80.4M |
| IPO Year | 2021 | N/A |
| Metric | ANEB | BTMD |
|---|---|---|
| Price | $1.15 | $2.68 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 103.1K | ★ 116.0K |
| Earning Date | 02-13-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 270.48 |
| EPS | N/A | ★ 0.78 |
| Revenue | N/A | ★ $195,645,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2.80 |
| P/E Ratio | ★ N/A | $3.56 |
| Revenue Growth | N/A | ★ 1.34 |
| 52 Week Low | $0.90 | $2.32 |
| 52 Week High | $3.42 | $6.36 |
| Indicator | ANEB | BTMD |
|---|---|---|
| Relative Strength Index (RSI) | 18.73 | 49.71 |
| Support Level | $1.14 | $2.56 |
| Resistance Level | $2.40 | $2.80 |
| Average True Range (ATR) | 0.19 | 0.14 |
| MACD | -0.12 | 0.01 |
| Stochastic Oscillator | 4.23 | 37.14 |
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies. Anebulo Pharmaceuticals operates in one segment, exclusively in the United States.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company derives revenue from United States and also has its presence in other countries.